"10.1371_journal.pone.0101510","plos one","2014-07-03T00:00:00Z","Michael A Pfaller; David R Andes; Daniel J Diekema; David L Horn; Annette C Reboli; Coleman Rotstein; Billy Franks; Nkechi E Azie","JMI Laboratories, North Liberty, Iowa, United States of America; Department of Pathology, University of Iowa, Iowa City, Iowa, United States of America; Department of Medicine, University of Wisconsin, Madison, Wisconsin, United States of America; David Horn LLC, Doylestown, Pennsylvania, United States of America; Department of Medicine, Cooper Medical School of Rowan University, Camden, New Jersey, United States of America; Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Astellas Scientific and Medical Affairs, Northbrook, Illinois, United States of America","Conceived and designed the experiments: MP BF DH CR DA. Performed the experiments: MP DH CR DD DA. Analyzed the data: MP BF DH CR NA AR DD DA. Contributed reagents/materials/analysis tools: BF NA. Wrote the paper: MP BF DH CR NA AR DD DA.","The authors have read the journals policy and declare the following conflicts: MAP has received grant support and sat on advisory boards for Astellas Pharma, Merck and Pfizer. He is a consultant for JMI laboratories. DRA has received grant support from Astellas Pharma and consultancy fees from Merck. He is also a member of the PLOS ONE editorial board. DJD has received grant support from Astellas. DLH is a principal of David Horn, LLC and CEO of a private company, Mid-Atlantic BioTherapeutics, Inc. He has received consultancy fees from Astellas Pharma. ACR has received grant support from Merck and T3 Biosystems. CR has received grant support and Honoraria from Astellas Pharma and Honoraria from Merck and Pfizer. BF and NEA are employees of Astellas Pharma. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","07","Michael A Pfaller","MAP",8,TRUE,5,5,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
